XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy
Phase II study of second line capecitabine plus oxaliplatin (XELOX) in patients with advanced biliary tract carcinoma after failure of gemcitabine-based chemotherapy.
Biliary Tract Cancer
DRUG: capecitabine|DRUG: oxaliplatin
Progression-free survival, 12months
response rate, 12months|duration of response, 12months|overall survival, 12months|Number of Participants with Adverse Events as a Measure of Safety and Tolerability, 24months
XELOX

* Xeloda, 1000mg/㎡ bid, day 1-15, every 3 weeks
* Oxaliplatin 130mg/㎡, day 1, every 3 weeks Until disease progression, patient's refusal or up to 8 cycles (maximum).